Osteoprotegerin positively regulates hematopoietic progenitor cells.

Abstract

Osteoprotegerin (OPG), the soluble decoy receptor of RANKL is released by bone marrow osteoblasts and plays an important role in physiological osteoblastogenesis and pathological bone disease. In earlier studies, we have shown that generated stromal cell lines from the aorta-gonad-mesonephros (AGM)-region serving as good supporters of murine and human hematopoietic progenitor cell (HPC) expansion highly express OPG detected by microarray analysis. Here, we investigated the role of OPG to HPC expansion in vitro. Addition of OPG leads to an enhanced expansion of HPC in liquid culture. In addition, progenitor cell function, measured by colony and cobblestone formation, was increased. The observed effects were partially antagonized by addition of RANKL. In conclusion, these findings suggest an important role of OPG maintaining progenitor cell function in the osteoblastic niche.

• Authors: Eric Schweikle, Tina Baessler, Sedat Yildirim, Lothar Kanz, Robert Möhle, Katja C Weisel
• Journal: Current stem cell research & therapy (Curr Stem Cell Res Ther) Vol. 7 Issue 1 Pg. 72-7 (Jan 2012) ISSN: 2212-3946 [Electronic] United Arab Emirates
• PMID: 22023625 (Publication Type: Journal Article)

Chemical References

• Antigens, CD34
• Osteoprotegerin
• RANK Ligand

Topics

• Antigens, CD34 (metabolism)
• Bone Diseases (drug therapy, metabolism, pathology)
• Cell Growth Processes (drug effects)
• Cells, Cultured
• Gene Expression Regulation, Developmental (drug effects)
• Hematopoiesis (drug effects)
• Hematopoietic Stem Cell Transplantation
• Hematopoietic Stem Cells (drug effects, physiology)
• Humans
• Microarray Analysis
• Osteoblasts (metabolism, pathology)
• Osteogenesis (drug effects)
• Osteoprotegerin (genetics, metabolism, pharmacology)
• RANK Ligand (antagonists & inhibitors, pharmacology)